世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

CD19ターゲット薬の世界市場成長 2023-2029


Global CD19 Target Drug Market Growth 2023-2029

LPI(LPインフォメーション)の最新調査によると、世界のCD19標的薬の市場規模は2022年に100万米ドルと評価されました。下流市場での需要の増加に伴い、CD19標的薬は2029年までに100万米ドルの再調整された規模に... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
LP Information
LPインフォメーション
2023年11月7日 US$3,660
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
95 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

LPI(LPインフォメーション)の最新調査によると、世界のCD19標的薬の市場規模は2022年に100万米ドルと評価されました。下流市場での需要の増加に伴い、CD19標的薬は2029年までに100万米ドルの再調整された規模になると予測され、レビュー期間中の年平均成長率は%です。
この調査レポートは、世界のCD19標的薬市場の成長の可能性を明らかにしています。CD19ターゲット薬は今後の市場でも安定した成長が期待されます。しかし、CD19標的薬の普及には、製品の差別化、コスト削減、サプライチェーンの最適化が引き続き重要です。CD19ターゲット薬市場がもたらす大きなチャンスを生かすためには、市場参入企業は研究開発に投資し、戦略的パートナーシップを構築し、進化する消費者の嗜好に合わせた製品を提供する必要がある。
CD19標的薬は、特定のタイプのB細胞関連疾患の治療に用いられる薬剤の一種である。これらの薬剤は、B細胞表面のCD19抗原を標的とすることにより、免疫系の機能を阻害する。CD19(Cluster of Differentiation 19)は細胞表面抗原で、通常Bリンパ球の表面に発現するが、T細胞やNK細胞、その他の免疫細胞には発現しない。CD19抗原を標的とする薬剤は、B細胞リンパ腫やその他のB細胞関連疾患の治療に用いられる。
主な特徴
CD19抗原を標的とする薬剤市場に関する本レポートは、様々な側面を反映し、業界に関する貴重な洞察を提供します。
市場規模と成長:この調査レポートは、CD19標的薬市場の現在の規模と成長の概要を提供します。過去データ、タイプ別市場区分(CD19ターゲット、CD19+CD3ターゲットなど)、地域別内訳などが含まれます。
市場促進要因と課題:政府規制、環境問題、技術の進歩、消費者の嗜好の変化など、CD19ターゲット医薬品市場の成長を促進する要因を特定・分析することができます。また、インフラストラクチャーの制限、射程距離への不安、高額な初期費用など、業界が直面する課題も浮き彫りにすることができます。
競合情勢:この調査レポートは、CD19標的薬市場内の競合状況の分析を提供しています。主要企業のプロフィール、市場シェア、戦略、製品提供などが含まれています。また、新興プレーヤーとその潜在的な市場への影響も強調することができます。
技術開発:調査レポートは、CD19標的薬業界における最新の技術開発を掘り下げることができます。これには、CD19標的薬技術の進歩、CD19標的薬の新規参入、CD19標的薬の新規投資、CD19標的薬の将来を形作るその他の技術革新が含まれます。
川下企業の好み:本レポートは、CD19標的薬市場における顧客の購買行動や採用動向を明らかにします。顧客の購買決定やCD19標的薬製品の嗜好に影響を与える要因も含まれています。
政府の政策とインセンティブ調査レポートは、CD19標的薬市場に対する政府の政策とインセンティブの影響を分析します。これには、CD19標的薬市場の促進を目的とした規制の枠組み、補助金、税制優遇措置などの評価が含まれます。また、市場成長促進におけるこれらの政策の有効性も評価します。
環境への影響と持続可能性CD19ターゲット医薬品市場の環境への影響と持続可能性の側面を評価しています。
市場予測と将来展望:調査レポートでは、実施した分析に基づいて、CD19標的薬産業の市場予測と展望を提供しています。これには、市場規模、成長率、地域動向、技術進歩や政策展開に関する予測などが含まれます。
提言と機会本レポートは、業界関係者、政策立案者、投資家への提言で締めくくられています。市場関係者が新たなトレンドを活用し、課題を克服し、CD19標的薬市場の成長と発展に貢献するための潜在的な機会を強調しています。
市場の細分化
CD19ターゲット医薬品市場は、タイプ別と用途別に分類されます。2018年から2029年までの期間について、セグメント間の成長により、タイプ別、用途別の消費額の正確な計算と予測を数量と金額で提供します。
タイプ別セグメント
CD19ターゲット
CD19+CD3ターゲット
CD19+DNAターゲット
用途別セグメント
リンパ腫
急性リンパ芽球性白血病
その他
本レポートでは、市場を地域別にも分割しています:
南北アメリカ
アメリカ
カナダ
メキシコ
ブラジル
APAC
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
中東・アフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下の企業は、一次専門家から収集した情報、および企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。
ADCセラピューティクスSA
ブリストル・マイヤーズ スクイブ
カイトファーマ
ヴィエラ・バイオ
ノバルティスファーマAG
アムジェン社
ユベンタス
フォスファーマ
JWセラピューティクス
本レポートで扱う主な質問
CD19標的薬の世界市場の10年見通しは?
CD19標的薬の世界市場および地域別市場成長の要因は何か?
市場別、地域別に最も急成長する技術は何か?
CD19標的薬の市場機会は最終市場規模によってどのように異なるのか?
CD19標的薬のタイプ別、用途別内訳は?


ページTOPに戻る


目次

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global CD19 Target Drug Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for CD19 Target Drug by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for CD19 Target Drug by Country/Region, 2018, 2022 & 2029
2.2 CD19 Target Drug Segment by Type
2.2.1 CD19 Target
2.2.2 CD19+CD3 Target
2.2.3 CD19+DNA Target
2.3 CD19 Target Drug Sales by Type
2.3.1 Global CD19 Target Drug Sales Market Share by Type (2018-2023)
2.3.2 Global CD19 Target Drug Revenue and Market Share by Type (2018-2023)
2.3.3 Global CD19 Target Drug Sale Price by Type (2018-2023)
2.4 CD19 Target Drug Segment by Application
2.4.1 Lymphoma
2.4.2 Acute Lymphoblastic Leukemia
2.4.3 Other
2.5 CD19 Target Drug Sales by Application
2.5.1 Global CD19 Target Drug Sale Market Share by Application (2018-2023)
2.5.2 Global CD19 Target Drug Revenue and Market Share by Application (2018-2023)
2.5.3 Global CD19 Target Drug Sale Price by Application (2018-2023)
3 Global CD19 Target Drug by Company
3.1 Global CD19 Target Drug Breakdown Data by Company
3.1.1 Global CD19 Target Drug Annual Sales by Company (2018-2023)
3.1.2 Global CD19 Target Drug Sales Market Share by Company (2018-2023)
3.2 Global CD19 Target Drug Annual Revenue by Company (2018-2023)
3.2.1 Global CD19 Target Drug Revenue by Company (2018-2023)
3.2.2 Global CD19 Target Drug Revenue Market Share by Company (2018-2023)
3.3 Global CD19 Target Drug Sale Price by Company
3.4 Key Manufacturers CD19 Target Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers CD19 Target Drug Product Location Distribution
3.4.2 Players CD19 Target Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for CD19 Target Drug by Geographic Region
4.1 World Historic CD19 Target Drug Market Size by Geographic Region (2018-2023)
4.1.1 Global CD19 Target Drug Annual Sales by Geographic Region (2018-2023)
4.1.2 Global CD19 Target Drug Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic CD19 Target Drug Market Size by Country/Region (2018-2023)
4.2.1 Global CD19 Target Drug Annual Sales by Country/Region (2018-2023)
4.2.2 Global CD19 Target Drug Annual Revenue by Country/Region (2018-2023)
4.3 Americas CD19 Target Drug Sales Growth
4.4 APAC CD19 Target Drug Sales Growth
4.5 Europe CD19 Target Drug Sales Growth
4.6 Middle East & Africa CD19 Target Drug Sales Growth
5 Americas
5.1 Americas CD19 Target Drug Sales by Country
5.1.1 Americas CD19 Target Drug Sales by Country (2018-2023)
5.1.2 Americas CD19 Target Drug Revenue by Country (2018-2023)
5.2 Americas CD19 Target Drug Sales by Type
5.3 Americas CD19 Target Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC CD19 Target Drug Sales by Region
6.1.1 APAC CD19 Target Drug Sales by Region (2018-2023)
6.1.2 APAC CD19 Target Drug Revenue by Region (2018-2023)
6.2 APAC CD19 Target Drug Sales by Type
6.3 APAC CD19 Target Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe CD19 Target Drug by Country
7.1.1 Europe CD19 Target Drug Sales by Country (2018-2023)
7.1.2 Europe CD19 Target Drug Revenue by Country (2018-2023)
7.2 Europe CD19 Target Drug Sales by Type
7.3 Europe CD19 Target Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa CD19 Target Drug by Country
8.1.1 Middle East & Africa CD19 Target Drug Sales by Country (2018-2023)
8.1.2 Middle East & Africa CD19 Target Drug Revenue by Country (2018-2023)
8.2 Middle East & Africa CD19 Target Drug Sales by Type
8.3 Middle East & Africa CD19 Target Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of CD19 Target Drug
10.3 Manufacturing Process Analysis of CD19 Target Drug
10.4 Industry Chain Structure of CD19 Target Drug
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 CD19 Target Drug Distributors
11.3 CD19 Target Drug Customer
12 World Forecast Review for CD19 Target Drug by Geographic Region
12.1 Global CD19 Target Drug Market Size Forecast by Region
12.1.1 Global CD19 Target Drug Forecast by Region (2024-2029)
12.1.2 Global CD19 Target Drug Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global CD19 Target Drug Forecast by Type
12.7 Global CD19 Target Drug Forecast by Application
13 Key Players Analysis
13.1 ADC Therapeutics SA
13.1.1 ADC Therapeutics SA Company Information
13.1.2 ADC Therapeutics SA CD19 Target Drug Product Portfolios and Specifications
13.1.3 ADC Therapeutics SA CD19 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 ADC Therapeutics SA Main Business Overview
13.1.5 ADC Therapeutics SA Latest Developments
13.2 Bristol Myers Squibb
13.2.1 Bristol Myers Squibb Company Information
13.2.2 Bristol Myers Squibb CD19 Target Drug Product Portfolios and Specifications
13.2.3 Bristol Myers Squibb CD19 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Bristol Myers Squibb Main Business Overview
13.2.5 Bristol Myers Squibb Latest Developments
13.3 Kite Pharma, Inc.
13.3.1 Kite Pharma, Inc. Company Information
13.3.2 Kite Pharma, Inc. CD19 Target Drug Product Portfolios and Specifications
13.3.3 Kite Pharma, Inc. CD19 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Kite Pharma, Inc. Main Business Overview
13.3.5 Kite Pharma, Inc. Latest Developments
13.4 Viela Bio
13.4.1 Viela Bio Company Information
13.4.2 Viela Bio CD19 Target Drug Product Portfolios and Specifications
13.4.3 Viela Bio CD19 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Viela Bio Main Business Overview
13.4.5 Viela Bio Latest Developments
13.5 Novartis Pharma AG
13.5.1 Novartis Pharma AG Company Information
13.5.2 Novartis Pharma AG CD19 Target Drug Product Portfolios and Specifications
13.5.3 Novartis Pharma AG CD19 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Novartis Pharma AG Main Business Overview
13.5.5 Novartis Pharma AG Latest Developments
13.6 Amgen, Inc.
13.6.1 Amgen, Inc. Company Information
13.6.2 Amgen, Inc. CD19 Target Drug Product Portfolios and Specifications
13.6.3 Amgen, Inc. CD19 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Amgen, Inc. Main Business Overview
13.6.5 Amgen, Inc. Latest Developments
13.7 Juventas
13.7.1 Juventas Company Information
13.7.2 Juventas CD19 Target Drug Product Portfolios and Specifications
13.7.3 Juventas CD19 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Juventas Main Business Overview
13.7.5 Juventas Latest Developments
13.8 FOSUN PHARMA
13.8.1 FOSUN PHARMA Company Information
13.8.2 FOSUN PHARMA CD19 Target Drug Product Portfolios and Specifications
13.8.3 FOSUN PHARMA CD19 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 FOSUN PHARMA Main Business Overview
13.8.5 FOSUN PHARMA Latest Developments
13.9 JW Therapeutics
13.9.1 JW Therapeutics Company Information
13.9.2 JW Therapeutics CD19 Target Drug Product Portfolios and Specifications
13.9.3 JW Therapeutics CD19 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 JW Therapeutics Main Business Overview
13.9.5 JW Therapeutics Latest Developments
14 Research Findings and Conclusion

 

ページTOPに戻る


 

Summary

According to our LPI (LP Information) latest study, the global CD19 Target Drug market size was valued at US$ million in 2022. With growing demand in downstream market, the CD19 Target Drug is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during review period.
The research report highlights the growth potential of the global CD19 Target Drug market. CD19 Target Drug are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of CD19 Target Drug. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the CD19 Target Drug market.
CD19-target drugs are a class of drugs used to treat specific types of B cell-related diseases. These drugs interfere with the function of the immune system by targeting the CD19 antigen on the surface of B cells. CD19 (Cluster of Differentiation 19) is a cell surface antigen that is usually expressed on the surface of B lymphocytes, but not on T cells, NK cells or other immune cells. Drugs targeting the CD19 antigen are used to treat B-cell lymphoma and other B-cell-related diseases.
Key Features:
The report on CD19 Target Drug market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the CD19 Target Drug market. It may include historical data, market segmentation by Type (e.g., CD19 Target, CD19+CD3 Target), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the CD19 Target Drug market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the CD19 Target Drug market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the CD19 Target Drug industry. This include advancements in CD19 Target Drug technology, CD19 Target Drug new entrants, CD19 Target Drug new investment, and other innovations that are shaping the future of CD19 Target Drug.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the CD19 Target Drug market. It includes factors influencing customer ' purchasing decisions, preferences for CD19 Target Drug product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the CD19 Target Drug market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting CD19 Target Drug market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the CD19 Target Drug market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the CD19 Target Drug industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the CD19 Target Drug market.
Market Segmentation:
CD19 Target Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
CD19 Target
CD19+CD3 Target
CD19+DNA Target
Segmentation by application
Lymphoma
Acute Lymphoblastic Leukemia
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
ADC Therapeutics SA
Bristol Myers Squibb
Kite Pharma, Inc.
Viela Bio
Novartis Pharma AG
Amgen, Inc.
Juventas
FOSUN PHARMA
JW Therapeutics
Key Questions Addressed in this Report
What is the 10-year outlook for the global CD19 Target Drug market?
What factors are driving CD19 Target Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do CD19 Target Drug market opportunities vary by end market size?
How does CD19 Target Drug break out type, application?



ページTOPに戻る


Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global CD19 Target Drug Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for CD19 Target Drug by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for CD19 Target Drug by Country/Region, 2018, 2022 & 2029
2.2 CD19 Target Drug Segment by Type
2.2.1 CD19 Target
2.2.2 CD19+CD3 Target
2.2.3 CD19+DNA Target
2.3 CD19 Target Drug Sales by Type
2.3.1 Global CD19 Target Drug Sales Market Share by Type (2018-2023)
2.3.2 Global CD19 Target Drug Revenue and Market Share by Type (2018-2023)
2.3.3 Global CD19 Target Drug Sale Price by Type (2018-2023)
2.4 CD19 Target Drug Segment by Application
2.4.1 Lymphoma
2.4.2 Acute Lymphoblastic Leukemia
2.4.3 Other
2.5 CD19 Target Drug Sales by Application
2.5.1 Global CD19 Target Drug Sale Market Share by Application (2018-2023)
2.5.2 Global CD19 Target Drug Revenue and Market Share by Application (2018-2023)
2.5.3 Global CD19 Target Drug Sale Price by Application (2018-2023)
3 Global CD19 Target Drug by Company
3.1 Global CD19 Target Drug Breakdown Data by Company
3.1.1 Global CD19 Target Drug Annual Sales by Company (2018-2023)
3.1.2 Global CD19 Target Drug Sales Market Share by Company (2018-2023)
3.2 Global CD19 Target Drug Annual Revenue by Company (2018-2023)
3.2.1 Global CD19 Target Drug Revenue by Company (2018-2023)
3.2.2 Global CD19 Target Drug Revenue Market Share by Company (2018-2023)
3.3 Global CD19 Target Drug Sale Price by Company
3.4 Key Manufacturers CD19 Target Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers CD19 Target Drug Product Location Distribution
3.4.2 Players CD19 Target Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for CD19 Target Drug by Geographic Region
4.1 World Historic CD19 Target Drug Market Size by Geographic Region (2018-2023)
4.1.1 Global CD19 Target Drug Annual Sales by Geographic Region (2018-2023)
4.1.2 Global CD19 Target Drug Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic CD19 Target Drug Market Size by Country/Region (2018-2023)
4.2.1 Global CD19 Target Drug Annual Sales by Country/Region (2018-2023)
4.2.2 Global CD19 Target Drug Annual Revenue by Country/Region (2018-2023)
4.3 Americas CD19 Target Drug Sales Growth
4.4 APAC CD19 Target Drug Sales Growth
4.5 Europe CD19 Target Drug Sales Growth
4.6 Middle East & Africa CD19 Target Drug Sales Growth
5 Americas
5.1 Americas CD19 Target Drug Sales by Country
5.1.1 Americas CD19 Target Drug Sales by Country (2018-2023)
5.1.2 Americas CD19 Target Drug Revenue by Country (2018-2023)
5.2 Americas CD19 Target Drug Sales by Type
5.3 Americas CD19 Target Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC CD19 Target Drug Sales by Region
6.1.1 APAC CD19 Target Drug Sales by Region (2018-2023)
6.1.2 APAC CD19 Target Drug Revenue by Region (2018-2023)
6.2 APAC CD19 Target Drug Sales by Type
6.3 APAC CD19 Target Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe CD19 Target Drug by Country
7.1.1 Europe CD19 Target Drug Sales by Country (2018-2023)
7.1.2 Europe CD19 Target Drug Revenue by Country (2018-2023)
7.2 Europe CD19 Target Drug Sales by Type
7.3 Europe CD19 Target Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa CD19 Target Drug by Country
8.1.1 Middle East & Africa CD19 Target Drug Sales by Country (2018-2023)
8.1.2 Middle East & Africa CD19 Target Drug Revenue by Country (2018-2023)
8.2 Middle East & Africa CD19 Target Drug Sales by Type
8.3 Middle East & Africa CD19 Target Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of CD19 Target Drug
10.3 Manufacturing Process Analysis of CD19 Target Drug
10.4 Industry Chain Structure of CD19 Target Drug
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 CD19 Target Drug Distributors
11.3 CD19 Target Drug Customer
12 World Forecast Review for CD19 Target Drug by Geographic Region
12.1 Global CD19 Target Drug Market Size Forecast by Region
12.1.1 Global CD19 Target Drug Forecast by Region (2024-2029)
12.1.2 Global CD19 Target Drug Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global CD19 Target Drug Forecast by Type
12.7 Global CD19 Target Drug Forecast by Application
13 Key Players Analysis
13.1 ADC Therapeutics SA
13.1.1 ADC Therapeutics SA Company Information
13.1.2 ADC Therapeutics SA CD19 Target Drug Product Portfolios and Specifications
13.1.3 ADC Therapeutics SA CD19 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 ADC Therapeutics SA Main Business Overview
13.1.5 ADC Therapeutics SA Latest Developments
13.2 Bristol Myers Squibb
13.2.1 Bristol Myers Squibb Company Information
13.2.2 Bristol Myers Squibb CD19 Target Drug Product Portfolios and Specifications
13.2.3 Bristol Myers Squibb CD19 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Bristol Myers Squibb Main Business Overview
13.2.5 Bristol Myers Squibb Latest Developments
13.3 Kite Pharma, Inc.
13.3.1 Kite Pharma, Inc. Company Information
13.3.2 Kite Pharma, Inc. CD19 Target Drug Product Portfolios and Specifications
13.3.3 Kite Pharma, Inc. CD19 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Kite Pharma, Inc. Main Business Overview
13.3.5 Kite Pharma, Inc. Latest Developments
13.4 Viela Bio
13.4.1 Viela Bio Company Information
13.4.2 Viela Bio CD19 Target Drug Product Portfolios and Specifications
13.4.3 Viela Bio CD19 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Viela Bio Main Business Overview
13.4.5 Viela Bio Latest Developments
13.5 Novartis Pharma AG
13.5.1 Novartis Pharma AG Company Information
13.5.2 Novartis Pharma AG CD19 Target Drug Product Portfolios and Specifications
13.5.3 Novartis Pharma AG CD19 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Novartis Pharma AG Main Business Overview
13.5.5 Novartis Pharma AG Latest Developments
13.6 Amgen, Inc.
13.6.1 Amgen, Inc. Company Information
13.6.2 Amgen, Inc. CD19 Target Drug Product Portfolios and Specifications
13.6.3 Amgen, Inc. CD19 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Amgen, Inc. Main Business Overview
13.6.5 Amgen, Inc. Latest Developments
13.7 Juventas
13.7.1 Juventas Company Information
13.7.2 Juventas CD19 Target Drug Product Portfolios and Specifications
13.7.3 Juventas CD19 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Juventas Main Business Overview
13.7.5 Juventas Latest Developments
13.8 FOSUN PHARMA
13.8.1 FOSUN PHARMA Company Information
13.8.2 FOSUN PHARMA CD19 Target Drug Product Portfolios and Specifications
13.8.3 FOSUN PHARMA CD19 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 FOSUN PHARMA Main Business Overview
13.8.5 FOSUN PHARMA Latest Developments
13.9 JW Therapeutics
13.9.1 JW Therapeutics Company Information
13.9.2 JW Therapeutics CD19 Target Drug Product Portfolios and Specifications
13.9.3 JW Therapeutics CD19 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 JW Therapeutics Main Business Overview
13.9.5 JW Therapeutics Latest Developments
14 Research Findings and Conclusion

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同じKEY WORD(drug)の最新刊レポート


よくあるご質問


LP Information社はどのような調査会社ですか?


LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/12/23 10:26

157.72 円

164.94 円

201.11 円

ページTOPに戻る